MammoWave | Cutting edge microwave imaging device for safe and accurate breast cancer screening

Summary
Breast cancer (BC) is the most prevalent form of cancer in women. One in nine women will acquire BC at some point in their life and one in thirty will die from the disease . Most EU countries have adopted mass BC screening programmes as a way for detecting the disease early, using tools such as mammography machines. Mammography has been the medical industry’s “gold standard” breast cancer screening tool for nearly four decades. However, a number of adverse effects, backed up by mounting scientific evidence, are now limiting the use of mammography as a mass screening device.
MammoWave is a revolutionary BC screening device for highly accurate cancer detection based on safe microwaves instead of ionizing radiation (X-rays).
The excellent overall sensitivity (ongoing clinical trials show sensitivity above 90%), the simple method that requires no squishing of the breast, and the complete safety of the microwave imaging technique, make MammoWave primed for mass BC screening.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/830265
Start date: 01-10-2018
End date: 31-08-2021
Total budget - Public funding: 1 990 163,50 Euro - 1 393 114,00 Euro
Cordis data

Original description

Breast cancer (BC) is the most prevalent form of cancer in women. One in nine women will acquire BC at some point in their life and one in thirty will die from the disease . Most EU countries have adopted mass BC screening programmes as a way for detecting the disease early, using tools such as mammography machines. Mammography has been the medical industry’s “gold standard” breast cancer screening tool for nearly four decades. However, a number of adverse effects, backed up by mounting scientific evidence, are now limiting the use of mammography as a mass screening device.
MammoWave is a revolutionary BC screening device for highly accurate cancer detection based on safe microwaves instead of ionizing radiation (X-rays).
The excellent overall sensitivity (ongoing clinical trials show sensitivity above 90%), the simple method that requires no squishing of the breast, and the complete safety of the microwave imaging technique, make MammoWave primed for mass BC screening.

Status

CLOSED

Call topic

EIC-SMEInst-2018-2020

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.0. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-2
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.0. INDUSTRIAL LEADERSHIP - Innovation In SMEs - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-2
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.0. Cross-cutting call topics
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-2